Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03845660 · ClinicalTrials.gov registry record · NA
Risk EValuation And Its Impact on ClinicAL Decision Making and Outcomes in Heart Failure
A NA study of Heart Failure, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 3,124
- Enrollment target
- 1
- Study location
NCT03845660: Completed NA study of Heart Failure, sponsored by Yale University.
NCT03845660 is a NA study of Heart Failure that has completed, run by Yale University. The registered enrollment target is 3,124 participants, above the 2,041-participant average among 397 other Heart Failure trials with a reported enrollment target (53% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03845660, a NA study of Heart Failure, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,124 participants
- Enrollment target
- 1
- Study location
Study Summary
Heart failure is a complex and heterogenous disease with mortality and morbidity that equals more cancers. Numerous studies have examined the ability to improve prognostication from heart failure, ranging from basic statistical methodologies to machine learning, with impressive improvements in both predictive indices. However, no study to date has examined, in a randomized fashion, the impact of providing prognostic information on provider behavior and downstream clinical outcomes. It is for this reason that the investigators plan to perform the Risk EValuation And Its Impact on ClinicAL Decision Making and Outcomes in Heart Failure (REVeAL-HF) Trial within the Yale New Haven Health System. REVeAL-HF is a randomized, single-blind intervention trial that is testing the clinical impact of providing prognostic information to the provider on heart failure outcomes in the inpatient settings. The study hypothesis is that electronic alerting about prognostic information on heart failure patients along with links to guidelines will lead to reductions in all-cause mortality and 30-day HF hospitalizations via improved use of guideline directed medical therapy and more adequate decongestion.
Primary Outcome
All cause mortality will be monitored and reported.
Conditions Studied
Interventions
- BEHAVIORAL Electronic Alert
Study Locations (1)
Connecticut
- Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,124 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2021-12-30 |
| Phase | NA |
What the finished NCT03845660 record still lists
NCT03845660 is an interventional study that assigns participants to a tested intervention. Its 3,124 participants enrollment target places it among the larger protocols in the corpus, above the 2,041-participant average among 397 other Heart Failure trials with a reported enrollment target (53% higher).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Electronic Alert is the first listed.
NCT03845660 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03845660 about?
NCT03845660 is a clinical study titled "Risk EValuation And Its Impact on ClinicAL Decision Making and Outcomes in Heart Failure". Heart failure is a complex and heterogenous disease with mortality and morbidity that equals more cancers. Numerous studies have examined the ability to improve prognostication from heart failure, ranging from basic statistical methodologies to machine learning, with impressive improvements in both ...
What is the current status of trial NCT03845660?
This trial is currently completed. It is a NA study. The enrollment target is 3,124 participants. The study started on 2020-01-01. Estimated completion is 2021-12-30.
What conditions does trial NCT03845660 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT03845660?
The interventions under investigation include: Electronic Alert (BEHAVIORAL).
Who is sponsoring clinical trial NCT03845660?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03845660 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03845660's enrollment target sits among peer trials
3,124 34th of 397 higher than 364 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05051722 · 3,110 participants
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- NCT04722822 · 3,100 participants · NA
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
- NCT06224205 · 3,150 participants · NA
Digital Detection of Dementia (D Cubed) Studies: D3
- NCT05534243 · 3,090 participants · NA
The ED-AWARENESS-2 Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI